Sotalol Mylan 80 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

sotalol mylan 80 mg tabletti

mylan ab - sotalol hydrochloride - tabletti - 80 mg - sotaloli

Sotacor 80 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

sotacor 80 mg tabletti

cheplapharm arzneimittel gmbh - sotalol hydrochloride - tabletti - 80 mg - sotaloli

Sitagliptin / Metformin hydrochloride Mylan Euroopan unioni - suomi - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Sitagliptin / Metformin hydrochloride Sun Euroopan unioni - suomi - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Dutasteride/Tamsulosinhydrochloride Mylan 0,5 mg / 0,4 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

dutasteride/tamsulosinhydrochloride mylan 0,5 mg / 0,4 mg kapseli, kova

mylan ab - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi

Dutasteride/Tamsulosinhydrochloride Sandoz 0,5 mg / 0,4 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

dutasteride/tamsulosinhydrochloride sandoz 0,5 mg / 0,4 mg kapseli, kova

sandoz a/s - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi

Minims Oxybuprocaine Hydrochloride 4 mg/ml silmätipat, liuos, kerta-annospakkaus Suomi - suomi - Fimea (Suomen lääkevirasto)

minims oxybuprocaine hydrochloride 4 mg/ml silmätipat, liuos, kerta-annospakkaus

bausch + lomb ireland limited - oxybuprocaine hydrochloride - silmätipat, liuos, kerta-annospakkaus - 4 mg/ml - oksibuprokaiini

Sitagliptin / Metformin hydrochloride Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Alfuzosin Hydrochloride Orion 10 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

alfuzosin hydrochloride orion 10 mg depottabletti

orion corporation - alfuzosin hydrochloride - depottabletti - 10 mg - alfutsosiini